Endocrinology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global endocrinology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 1–5 of 5 articles
Quick answer
NovaPharmaNews Endocrinology hub for FDA covers 5 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Neurocrine Biosciences pipeline update: what analysts should watch next
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome
Neurocrine Biosciences CRENESSITY Shows Sustained Benefits in Two-Year Pediatric CAH Study
FDA Encourages Testosterone Therapy Expansion for Low Libido in Men with Hypogonadism
FDA Approves Biosimilar Insulin Lispro: What You Need to Know
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.